Markets:

Overview

News

Currencies

International

Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

16.98 -0.25 (-1.45%)

Streaming Delayed Price Updated: 12:55 PM EDT, Jun 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >

1 Mooning Stock Worth Your Attention and 2 We Question

Today 0:38 EDT

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...

Via StockStory

1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky

June 17, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

3 Russell 2000 Stocks with Open Questions

June 10, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

Via StockStory

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase ↗

June 09, 2026

Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics...

Via MarketBeat

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Q4 2025 Earnings Beat on Strong Profitability ↗

February 27, 2026

Via Chartmill

Topics Earnings

Why Amneal (AMRX) Stock Is Trading Up Today

June 04, 2026

What Happened? Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 5.7% in the afternoon session after the U.S. Food and Drug Admini...

Via StockStory

3 Profitable Stocks with Open Questions

June 04, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Topics Economy

Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

May 26, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

2 Reasons AMRX is Risky and 1 Stock to Buy Instead

May 12, 2026

Amneal trades at $12.64 and has moved in lockstep with the market. Its shares have returned 6.2% over the last six months while the S&P 500 has gained 7.9%. ...

Via StockStory

Topics Artificial Intelligence Stocks

Amneal (AMRX) Q3 2025 Earnings Call Transcript ↗

May 04, 2026

Amneal (AMRX) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Amneal (AMRX) Q2 2025 Earnings Transcript ↗

May 04, 2026

Amneal (AMRX) Q2 2025 Earnings Transcript

Via The Motley Fool

Topics Supply Chain

1 Value Stock to Target This Week and 2 Facing Challenges

May 04, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

Amneal (AMRX) Q1 2026 Earnings Transcript ↗

May 01, 2026

Amneal (AMRX) Q1 2026 Earnings Transcript

Via The Motley Fool

Amneal (AMRX) Q1 Earnings Report Preview: What To Look For

April 29, 2026

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Friday before market hours. Here’s what you need to know. Amneal ...

Via StockStory

Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know

April 17, 2026

What Happened? A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy ...

Via StockStory

Topics Economy

2 Cash-Producing Stocks to Research Further and 1 We Brush Off

April 13, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Via StockStory

3 of Wall Street’s Favorite Stocks We Steer Clear Of

April 08, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

3 Small-Cap Stocks Walking a Fine Line

March 30, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment

March 10, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Reasons to Avoid AMRX and 1 Stock to Buy Instead

March 10, 2026

Amneal’s 34% return over the past six months has outpaced the S&P 500 by 30.9%, and its stock price has climbed to $13.16 per share. This performance may hav...

Via StockStory

Topics Stocks

3 Value Stocks We’re Skeptical Of

March 05, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Via StockStory

Why Amneal (AMRX) Stock Is Trading Lower Today

February 27, 2026

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell 6.3% in the afternoon session after the company reported fourth-quarter results that beat expectations but provided a...

Via StockStory

Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

Amneal (AMRX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations

February 27, 2026

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 11.5% year on year to $814.3 million. On the other hand,...

Via StockStory

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 25, 2026

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Friday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Supreme Court Strikes Down IEEPA Tariffs, Mandating Billions in Immediate Rebates

February 24, 2026

In a seismic shift for global trade and constitutional law, the Supreme Court of the United States ruled on February 20, 2026, that the executive branch lacks the authority to unilaterally impose...

Via MarketMinute

Topics Bonds Economy Government

3 Russell 2000 Stocks We Find Risky

February 12, 2026

Via StockStory

3 Small-Cap Stocks That Fall Short

February 04, 2026

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

3 Cash-Producing Stocks That Concern Us

February 01, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

3 Healthcare Stocks We Steer Clear Of

January 29, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also...

Via StockStory

Topics Stocks

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.